IMAC Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

IMAC Holdings prognostiziert ein Gewinnwachstum at 19.7% per annum. Der Gewinn pro Aktie wird voraussichtlich wachsen um 21.1% pro Jahr.

Wichtige Informationen

19.7%

Wachstumsrate der Gewinne

21.1%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	20.9%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	01 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

IMAC Holdings, Inc.'s (NASDAQ:BACK) Business And Shares Still Trailing The Industry

Apr 18

Is IMAC Holdings (NASDAQ:IMAC) Using Debt In A Risky Way?

Oct 12

IMAC expands Florida presence with Fort Pierce Chiropractic acquisition for undisclosed amount

Jun 14

We Think IMAC Holdings (NASDAQ:IMAC) Has A Fair Chunk Of Debt

Mar 06

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:BACK - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	N/A	-4	N/A	-4	1
12/31/2024	N/A	-3	N/A	-3	1
3/31/2024	N/A	-6	-2	-2	N/A
12/31/2023	N/A	-6	-3	-3	N/A
9/30/2023	-10	-6	-5	-5	N/A
6/30/2023	-8	-10	-6	-6	N/A
3/31/2023	-4	-10	-9	-9	N/A
12/31/2022	N/A	-12	-11	-10	N/A
9/30/2022	17	-14	-10	-10	N/A
6/30/2022	17	-11	-10	-9	N/A
3/31/2022	15	-11	-9	-8	N/A
12/31/2021	14	-11	-8	-8	N/A
9/30/2021	13	-8	-8	-8	N/A
6/30/2021	13	-7	-8	-7	N/A
3/31/2021	13	-6	-7	-7	N/A
12/31/2020	13	-6	-6	-6	N/A
9/30/2020	14	-7	-6	-5	N/A
6/30/2020	14	-7	-6	-5	N/A
3/31/2020	16	-7	-5	-4	N/A
12/31/2019	15	-6	-5	-4	N/A
9/30/2019	14	-6	-3	-3	N/A
6/30/2019	12	-5	-2	-3	N/A
3/31/2019	9	-4	-3	-2	N/A
12/31/2018	7	-3	-3	-2	N/A
9/30/2018	4	-2	-4	-2	N/A
6/30/2018	2	-1	-3	-1	N/A
3/31/2018	1	-1	-2	-1	N/A
12/31/2017	1	0	N/A	0	N/A
12/31/2016	0	0	N/A	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BACK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: BACK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: BACK wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von BACK schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: BACK wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BACK in 3 Jahren voraussichtlich hoch sein wird

IMAC Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 17% to US$1.25

Consensus forecasts updated

Price target decreased to US$5.00

Consensus estimates of losses per share improve by 10%

Price target decreased to US$5.50

Consensus EPS estimates fall to -US$0.38

Recent updates

IMAC Holdings Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10 Q

IMAC Holdings, Inc. announced delayed 10-Q filing

IMAC Holdings, Inc. announced that it expects to receive $3.74 million in funding from a group of investors

Imac Holdings Inc. Announces the Launch of an Entirely New Precision Oncology Assay for Breast Cancer Treatment Decision Making Utilizing the Reverse Phase Protein Array (Rppa) Technology Through Its Newly Established Subsidiary, Ignite Proteomics Llc

IMAC Holdings, Inc. Announces Resignation of Cary Sucoff as Director

IMAC Holdings, Inc. announced delayed 10-Q filing

IMAC Holdings, Inc. announced that it has received $1 million in funding

IMAC Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

IMAC Holdings, Inc. Announces Chief Executive Officer Changes

IMAC Holdings, Inc. Announces Board Resignations

Theralink Technologies, Inc. (OTCPK:THER) cancelled the acquisition of IMAC Holdings, Inc. (NasdaqCM:BACK) in a reverse merger transaction.

IMAC Holdings, Inc. announced delayed annual 10-K filing

Insufficient new directors

IMAC Holdings, Inc. Announces Executive Changes

IMAC Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement of $2.5 Million for Continued Listing on the Nasdaq Capital Market Under Listing Rule 5550(b)(1)

IMAC Holdings, Inc. announced delayed 10-Q filing

Insufficient new directors

IMAC Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

IMAC Holdings, Inc. Receive Non-Compliance Letter from Nasdaq

IMAC Holdings, Inc. Announces 1-for-30 Reverse Stock Split to Regain Compliance

Price target decreased by 17% to US$1.25

IMAC Holdings Provides Nasdaq Compliance Update Regarding Minimum Stockholders' Equity Requirement and Minimum Bid Price Requirement

IMAC Holdings, Inc. announced that it has received $4.3 million in funding from Theralink Technologies, Inc. and other investors

IMAC Holdings, Inc., Annual General Meeting, Jul 05, 2023

IMAC Holdings Receives A Non-Compliance Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Theralink Technologies, Inc. (OTCPK:THER) entered into a definitive agreement and plan of merger to acquire IMAC Holdings, Inc. (NasdaqCM:BACK) in a reverse merger transaction.

IMAC Holdings, Inc. announced delayed 10-Q filing

IMAC Holdings, Inc.'s (NASDAQ:BACK) Business And Shares Still Trailing The Industry

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$5.00

IMAC Holdings, Inc. Launches E-Commerce Website for Vitamin and Supplement Line

IMAC Holdings Receives Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

IMAC Holdings, Inc. Announces Completion of Third Cohort of Its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's Disease

Consensus estimates of losses per share improve by 10%

IMAC Holdings, Inc. Announces Addition of Medical Weight Loss Services to IMAC Regeneration Centers

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

IMAC Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $3.925 million.

IMAC Holdings, Inc. Adds Stretch Services At the Backspace

Price target decreased to US$5.50

IMAC Holdings, Inc. Announces the Launch of Spinal Health and Wellness Products and Supplements

IMAC Holdings, Inc., Annual General Meeting, Jul 06, 2022

IMAC Holdings, Inc. announced delayed annual 10-K filing

IMAC Holdings, Inc. Announces Completion of Second Cohort of Its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’S Disease

IMAC Holdings, Inc. Announces Executive Changes

Imac Holdings, Inc. Announces Relocates of Growing Clinic in St. Louis Area

Third quarter 2021 earnings released: US$0.068 loss per share (vs US$0.12 loss in 3Q 2020)

Is IMAC Holdings (NASDAQ:IMAC) Using Debt In A Risky Way?

Consensus EPS estimates fall to -US$0.38

Price target decreased to US$3.50

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.20 loss in 2Q 2020)

IMAC Holdings, Inc. Announces Initiation of Second Cohort of Its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease

IMAC Holdings Launches Acute Care Services for Musculoskeletal Injuries

IMAC Holdings, Inc. (NasdaqCM:IMAC) agreed to acquire Active Medical Center Ltd.

IMAC Holdings, Inc. (NasdaqCM:IMAC) acquired Fort Pierce Chiropractic.

IMAC expands Florida presence with Fort Pierce Chiropractic acquisition for undisclosed amount

Imac Holdings, Inc. Introduces the Back Space - First In-Store Chiropractic and Spinal Care Location Within Walmart

Consensus EPS estimates increase to -US$0.34

Consensus revenue estimates fall to US$14.3m

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.18 loss in 1Q 2020)

Analysts increase EPS estimates to -US$0.36

We Think IMAC Holdings (NASDAQ:IMAC) Has A Fair Chunk Of Debt

Full year 2020 earnings released: US$0.45 loss per share (vs US$0.84 loss in FY 2019)

Revenue and earnings miss expectations

IMAC Holdings, Inc. Announces Completion of First Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease

IMAC Holdings, Inc. Partners with Fortune 500 Company to Launch In-Store Spinal Care

IMAC Holdings, Inc. Adds Regenerative Wound Care Service in Regeneration Centers

New 90-day high: US$1.98

Gewinn- und Umsatzwachstumsprognosen